TIGIT and cancer: Afterward, we evaluated the link between DTYMK expression and key immune checkpoints (CD274, CTLA-4, HAVCR2, LAG3, PDCD1, PDCD1LG2, SIGLEC15, and TIGIT) expression levels in pan-cancer.